Matches in SemOpenAlex for { <https://semopenalex.org/work/W2747408029> ?p ?o ?g. }
Showing items 1 to 70 of
70
with 100 items per page.
- W2747408029 endingPage "810" @default.
- W2747408029 startingPage "808" @default.
- W2747408029 abstract "Objective To investigate the effects of different doses of dexmedetomidine on the minimum alveolar concentration (MAC) of sevoflurane required to inhibit the body movement evoked by skin incision.Methods ASA Ⅰ or Ⅱ patients of both sexes,aged 18-64 yr,with body mass index of 21-27 kg/m2,undegoing elective lower abdominal surgery under general anesthesia,were randomly divided into 4 groups:control group (group C) and different doses of dexmedetomidine groups (groups D1,D2 and D3 ).Dexmedetomidine 0.2,0.4 and 0.6 μg/kg in 15 ml of normal saline was infused over 30 min before induction of anesthesia in groups D1,D2 and D3 respectively.While 15 ml of normal saline was given instead in group C.Anesthesia was induced with inhalation of 8％ sevoflurane.The patients were mechanically ventilated after tracheal intubation.Anesthesia was maintained with inhalation of sevoflurane.The initial end-tidal concentration of sevoflurane was set at 3.0％,3.0％,2.5％,2.0％ in groups C,D1,D2 and D3 respectively.The ratio between the two successive concentrations was 0.9.Skin incision was made after 15 min of equilibratiton.At least 7 independent crossover pairs were observed in each group.The MAC of sevoflurane was the mean of the end-tidal concentration of sevoflurane of each crossover pair,and 95 ％ confidence interval (CI) was calculated.Results In groups C,D1,D2 and D3,18,20,20 and 22 patients were enrolled respectively.The MAC (95 ％ CI) of sevoflurane was 2.5 ％ (2.3 ％-2.8 ％ ),1.5 ％ ( 1.3 ％-1.7％),1.3％ (1.0％-1.6％) and 1.1％ (0.7％-1.5％) in groupsC,D1,D2 and D3 respectively.The MAC of sevoflurane was significantly lower in groups D1,D2,D3 than in group C,and in groups D2 and D3 than in group D1 ( P ＜ 0.05).There was no significant difference in the MAC of sevoflurane between groups D2 and D3 ( P ＞0.05).Conclusion Dexmedetomidine 0.2,0.4,0.6 μg/kg can significantly decrease the MAC of sevoflurane required to inhibit the body movement evoked by skin incision in a dose-dependent manner.Key words: Dexmedetomidine; Anesthetics, inhalation; Dose-response relationship, drug" @default.
- W2747408029 created "2017-08-31" @default.
- W2747408029 creator A5004184081 @default.
- W2747408029 creator A5009582245 @default.
- W2747408029 creator A5071968752 @default.
- W2747408029 creator A5088267604 @default.
- W2747408029 date "2012-07-20" @default.
- W2747408029 modified "2023-09-22" @default.
- W2747408029 title "Effects of different doses of dexmedetomidine on minimum alveolar concentration of sevoflurane required to inhibit the body movement evoked by skin incision" @default.
- W2747408029 doi "https://doi.org/10.3760/cma.j.issn.0254-1416.2012.07.009" @default.
- W2747408029 hasPublicationYear "2012" @default.
- W2747408029 type Work @default.
- W2747408029 sameAs 2747408029 @default.
- W2747408029 citedByCount "0" @default.
- W2747408029 crossrefType "journal-article" @default.
- W2747408029 hasAuthorship W2747408029A5004184081 @default.
- W2747408029 hasAuthorship W2747408029A5009582245 @default.
- W2747408029 hasAuthorship W2747408029A5071968752 @default.
- W2747408029 hasAuthorship W2747408029A5088267604 @default.
- W2747408029 hasConcept C126322002 @default.
- W2747408029 hasConcept C2776814716 @default.
- W2747408029 hasConcept C2776954882 @default.
- W2747408029 hasConcept C2777011798 @default.
- W2747408029 hasConcept C2777397205 @default.
- W2747408029 hasConcept C2781302539 @default.
- W2747408029 hasConcept C2781453256 @default.
- W2747408029 hasConcept C42219234 @default.
- W2747408029 hasConcept C44249647 @default.
- W2747408029 hasConcept C71924100 @default.
- W2747408029 hasConceptScore W2747408029C126322002 @default.
- W2747408029 hasConceptScore W2747408029C2776814716 @default.
- W2747408029 hasConceptScore W2747408029C2776954882 @default.
- W2747408029 hasConceptScore W2747408029C2777011798 @default.
- W2747408029 hasConceptScore W2747408029C2777397205 @default.
- W2747408029 hasConceptScore W2747408029C2781302539 @default.
- W2747408029 hasConceptScore W2747408029C2781453256 @default.
- W2747408029 hasConceptScore W2747408029C42219234 @default.
- W2747408029 hasConceptScore W2747408029C44249647 @default.
- W2747408029 hasConceptScore W2747408029C71924100 @default.
- W2747408029 hasIssue "7" @default.
- W2747408029 hasLocation W27474080291 @default.
- W2747408029 hasOpenAccess W2747408029 @default.
- W2747408029 hasPrimaryLocation W27474080291 @default.
- W2747408029 hasRelatedWork W2041871670 @default.
- W2747408029 hasRelatedWork W2349479664 @default.
- W2747408029 hasRelatedWork W2366438703 @default.
- W2747408029 hasRelatedWork W2385005625 @default.
- W2747408029 hasRelatedWork W2388592990 @default.
- W2747408029 hasRelatedWork W2408739354 @default.
- W2747408029 hasRelatedWork W2416686875 @default.
- W2747408029 hasRelatedWork W2591141383 @default.
- W2747408029 hasRelatedWork W3016431196 @default.
- W2747408029 hasRelatedWork W3028596570 @default.
- W2747408029 hasRelatedWork W3028866642 @default.
- W2747408029 hasRelatedWork W3028963327 @default.
- W2747408029 hasRelatedWork W3029625243 @default.
- W2747408029 hasRelatedWork W3030438989 @default.
- W2747408029 hasRelatedWork W3031849202 @default.
- W2747408029 hasRelatedWork W3032542121 @default.
- W2747408029 hasRelatedWork W30380060 @default.
- W2747408029 hasRelatedWork W2362134067 @default.
- W2747408029 hasRelatedWork W3030474267 @default.
- W2747408029 hasRelatedWork W3030641051 @default.
- W2747408029 hasVolume "32" @default.
- W2747408029 isParatext "false" @default.
- W2747408029 isRetracted "false" @default.
- W2747408029 magId "2747408029" @default.
- W2747408029 workType "article" @default.